Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elliot Stieglitz

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
European Journal of Human Genetics : EJHG|June 6, 2025
Biallelic SH2B3 germline variants are associated with a neonatal myeloproliferative disease and multisystemic involvementDavide Leardini, Elisabetta Flex, Elliot Stieglitz, et al.
Nature Communications|April 23, 2025
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemiaJuwita Werner, Alex G Lee, Chujing Zhang, et al.
Blood|June 4, 2017
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMMLAkihide Yoshimi, Maria E Balasis, Alexis Vedder, et al.
Haematologica|December 28, 2023
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemiaAstrid Wintering, Anna Hecht, Julia Meyer, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
<i>In vivo</i> validation of the palmitoylation cycle as a therapeutic target in <i>NRAS</i>-mutant cancerMatthew Decker, Benjamin J Huang, Timothy Ware, et al.
Haematologica|December 30, 2020
Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemiaAnna Hecht, Julia A Meyer, Astrid Behnert, et al.
American Journal of Human Genetics|May 28, 2019
Activating Mutations of RRAS2 Are a Rare Cause of Noonan SyndromeYline Capri, Elisabetta Flex, Oliver H F Krumbach, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
Analytical Chemistry|December 10, 2016
International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence VariantAlexandra S Whale, Alison S Devonshire, George Karlin-Neumann, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Human Genetics : EJHG|June 6, 2025
Biallelic SH2B3 germline variants are associated with a neonatal myeloproliferative disease and multisystemic involvementDavide Leardini, Elisabetta Flex, Elliot Stieglitz, et al.
Nature Communications|April 23, 2025
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemiaJuwita Werner, Alex G Lee, Chujing Zhang, et al.
Blood|June 4, 2017
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMMLAkihide Yoshimi, Maria E Balasis, Alexis Vedder, et al.
Haematologica|December 28, 2023
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemiaAstrid Wintering, Anna Hecht, Julia Meyer, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
<i>In vivo</i> validation of the palmitoylation cycle as a therapeutic target in <i>NRAS</i>-mutant cancerMatthew Decker, Benjamin J Huang, Timothy Ware, et al.
Haematologica|December 30, 2020
Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemiaAnna Hecht, Julia A Meyer, Astrid Behnert, et al.
American Journal of Human Genetics|May 28, 2019
Activating Mutations of RRAS2 Are a Rare Cause of Noonan SyndromeYline Capri, Elisabetta Flex, Oliver H F Krumbach, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
Analytical Chemistry|December 10, 2016
International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence VariantAlexandra S Whale, Alison S Devonshire, George Karlin-Neumann, et al.
Pageof 9